The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
- Investigator
- Ali Ataya
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
Critical Care Medicine Specialist, Pulmonologist (Lung Specialist)
My name is Dr. Ataya, and I am an associate professor of medicine in the University of Florida Division of Pulmonary, Critical Care & Sleep Medicine, director of the Pulmonary Hypertension Program and the HHT and Rare Lung Disease Program. I specialize in pulmonary disease, critical care medicine and internal medicine with clinical interest in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), hereditary hemorrhagic telangiectasia (HHT), lymphangioleiomyomatosis (LAM), pulmonary alveolar proteinosis (PAP) and other rare lung disorders.
My training started at the Royal College of Surgeons in Ireland (RCSI), where I earned my medical degree. I completed my internal medicine residency at the Cleveland Clinic in Ohio. Eventually, I completed my specialty training in pulmonary & critical care medicine here at UF in 2016. I am board certified by the American Board of Critical Care Medicine, American Board of Pulmonary Medicine and the American Board of Internal Medicine.
I maintain a membership of various medical professional societies, including the American Thoracic Society (ATS), America College of Chest Physicians (ACCP) and Pulmonary Hypertension Association (PHA). In addition, I am a strong patient advocate and am actively involved in various patient foundations.
I am involved in various clinical trials in the fields of pulmonary hypertension, intensive care medicine and rare pulmonary diseases.
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive…
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesMarch 13, 2024
A University of Florida Health pulmonologist has been appointed chair of a new state task force to study blood clots and make policy recommendations to protect…
College of Medicine, +2 more
June 28, 2022
The nosebleeds started in elementary school for Bernadette Guthrie as she furtively dabbed her nose with a tissue lest any classmate notice. “You certainly…
Department of Otolaryngology, +3 more